Newsroom | 18842 results

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its presence at the American Society of Genitourinary Cancers Symposium happening from February 26-28, 2026, in San Francisco, California. Flatiron's real-world data and research capabilities are featured across multiple presentations, including 6 research acceptances spanning genitourinary cancers. A cornerstone of Flatiron’s presence at ASCO GU 2026 is the global prostate cancer and bladder cancer Panoramic datasets, which draw from o...

BASEL, Zwitserland--(BUSINESS WIRE)--Swiss Rockets AG maakt bekend dat haar CoolMPS 600 mid-throughput sequencer met geavanceerde chemie en nieuwe MPS/NGS-readlengte in het tweede kwartaal van 2026 beschikbaar wordt. Mogelijk gemaakt door haar exclusieve licentie van CoolMPS-technologie, ontwikkelt Swiss Rockets AG sinds augustus 2025 haar eerste sequencer, CoolMPS 600, via contract-R&D met Complete Genomics. Het platform maakt gebruik van de eigen CoolMPS™-chemie van het bedrijf, gebaseerd...

BASILEA, Svizzera--(BUSINESS WIRE)--Swiss Rockets AG annuncia che CoolMPS 600, il suo sequenziatore a media produttività con chimica avanzata e nuova lunghezza di lettura MPS/NGS diventerà disponibile nel secondo trimestre 2026. Grazie alla sua licenza esclusiva di tecnologia CoolMPS, Swiss Rockets AG sta sviluppando il suo primo sequenziatore, CoolMPS 600, attraverso attività di ricerca e sviluppo a contratto con Complete Genomics fin dall'agosto 2025. La piattaforma sta utilizzando la tecnolo...

BÂLE, Suisse--(BUSINESS WIRE)--Swiss Rockets AG annonce que son séquenceur à débit moyen CoolMPS 600, présentant une chimie avancée et une nouvelle longueur de lecture MPS/NGS, sera disponible au deuxième trimestre 2026. Grâce à sa licence exclusive de la technologie CooIMPS, Swiss Rockets AG développe son premier séquenceur, le CoolMPS 600, dans le cadre d'un contrat de R&D avec Complete Genomics depuis août 2025. La plateforme utilise la chimie CoolMPS™, une technologie exclusive à base d...

BASILEA, Suiza--(BUSINESS WIRE)--Swiss Rockets AG anuncia que su secuenciador de rendimiento medio CoolMPS 600 con química avanzada y nueva longitud de lectura de secuenciación masiva paralela (MPS)/secuenciación de nueva generación (NGS) estará disponible en el segundo trimestre de 2026. Gracias a la licencia exclusiva de la tecnología CoolMPS, Swiss Rockets AG está desarrollando su primer secuenciador, CoolMPS 600, a través de una iniciativa de I+D por contrato junto a Complete Genomics desde...

BASEL, Schweiz--(BUSINESS WIRE)--Die Swiss Rockets AG gibt bekannt, dass ihr Sequenzierer CoolMPS 600 mit mittlerem Durchsatz, fortschrittlicher Chemie und neuartiger MPS/NGS-Read-Länge im zweiten Quartal 2026 auf den Markt kommen wird. Dank seiner exklusiven Lizenz für die CoolMPS-Technologie entwickelt Swiss Rockets AG seit August 2025 seinen ersten Sequenzer, CoolMPS 600, im Rahmen eines Forschungs- und Entwicklungsvertrags mit Complete Genomics. Die Plattform nutzt die firmeneigene, auf Ant...

BEVERLY, Mass.--(BUSINESS WIRE)--seqWell, a global leader in NGS library construction technology, today announced the launch of MosaiX, a next-generation library prep kit designed to streamline a wide range of high-throughput applications, including human WGS, large plant and animal genomics, and hybrid capture workflows such as Whole Exome Sequencing (WES) and other targeted panels. The announcement coincides with the Advances in Genome Biology and Technology (AGBT) General Meeting to be held...

BASEL, Switzerland--(BUSINESS WIRE)--Swiss Rockets AG announces that its CoolMPS 600 mid-throughput sequencer with advanced chemistry and novel MPS/NGS read length will become available in Q2 2026. Enabled by its exclusive license of CoolMPS technology, Swiss Rockets AG is developing its first sequencer, CoolMPS 600, through contract R&D with Complete Genomics since August 2025. The platform is utilizing the company’s proprietary antibody-based CoolMPS™ chemistry combined with DNBSEQ™, a re...

CAMBRIDGE, England & SAN DIEGO--(BUSINESS WIRE)--biomodal, an omics-based life sciences technology and analytics company, today announced at the AGBT 2026 General Meeting that biomodal’s duet multiomic solutions are compatible with Element Biosciences AVITI24™ 5D multiomics and AVITI™ sequencing instruments. Validated at the University of Minnesota (UMN) Genomics Center, this integration delivers enhanced sensitivity for applications including cancer, aging, and neurodegenerative disease with t...

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2025....